Intas launches immuno-booster add-on drug to standard Covid-19 treatment

Topics Intas | Pharma industry

The drug's anti-viral effects have been demonstrated via an in-vitro test against SARS-CoV2. Photo is representational.
In its bid to provide an add-on to standard Covid-19 treatment, drug maker Intas has launched a novel, patented research formulation of Thymoquinone under the brand name of Thymotas that fortifies immunity and ensures higher success in fighting infection. 

Tested clinically, the Thymotas 12.5 mg is successful in building immunity and combating infections effectively in the current pandemic, the company stated on Tuesday. According to Intas, Thymotas' anti-viral effects have been demonstrated via an in-vitro test against SARS-CoV2 and has tremendous potential as a potent add-on to the standard treatment in COVID-19.

Thymoquinone is the active biological component of Nigella sativa, also known as black cumin with various scientific publications available that prove its multiple pharmacologically beneficial properties. Also, in a first, Thymoquinone has been developed as a stable, standardized and ready-to-use tablet by Intas.

Apart from fortifying immunity, the Thymotas 12.5 mg formulation fights infections through multimodal actions such as anti-viral, anti-bacterial, anti-inflammatory, immuno-modulatory and antioxidant, said Dr Alok Chaturvedi, Senior Vice-President & Head-Medical Affairs at Intas. 

Manufactured in a WHO-GMP certified plant, Thymotas as an immunity booster & prophylaxis is recommended one tablet of 12.5 mg daily after meals or as directed by the physician. As an adjunct to infection treatment, Thymotas is recommended up to 50 mg per day after meals based on the severity of infection or as directed by the physician. 




Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel